PDCD1 and Patent ductus arteriosus: A recent study showed a relative increase in PD-1, TIGIT, and 4-1BB expression on peripheral circulating T cells (outside of the TME) in PDA patients receiving cytotoxic chemotherapy (31), but did not assess for other T cell checkpoint receptors or activation markers or intra-tumoral T cells.